Table 2.
Efficacy of Study Treatment
| Response | Cisplatin Plus Cetuximab (n = 115)
|
Cisplatin Alone (n = 58)
|
||
|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |
| Complete response | 2 | 2 | 1 | 2 |
|
| ||||
| Partial response | 21 | 18 | 5 | 9 |
|
| ||||
| Stable disease | 48 | 42 | 18 | 31 |
|
| ||||
| Progressive disease | 34 | 30 | 31 | 53 |
|
| ||||
| Not evaluable | 10 | 9 | 3 | 5 |
|
| ||||
| Best overall response rate | 23 | 20 | 6 | 10 |
|
| ||||
| 95% CI | 13 to 29 | 4 to 21 | ||
| Odds ratio* | 2.13 | |||
| 95% CI | 0.81 to 5.59 | |||
NOTE. Complete responses, partial responses, and stable disease were defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.
*
Stratified Cochran-Mantel-Haenszel test, P = .11.